ZNRF3
ZNRF3 (E3 ubiquitin-protein ligase ZNRF3) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Adrenocortical carcinoma.
Overview
E3 ubiquitin-protein ligase that acts as a negative regulator of the Wnt signalling pathway by mediating the ubiquitination and subsequent degradation of Wnt receptor complex components Frizzled and LRP6. Acts on both canonical and non-canonical Wnt signalling pathway. Acts as a tumour suppressor in the intestinal stem cell zone by inhibiting the Wnt signalling pathway, thereby restricting the size of the intestinal stem cell zone.
Open Targets scores its association with cancer at 0.55 (direct and indirect evidence; datatypes affected pathway 0.61, literature 0.94, genetic association 0.56, somatic mutation 0.47, animal model 0.41). IntOGen calls it a driver in 1 cohort (0 activating, 1 loss-of-function), covering Adrenocortical Carcinoma.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · ZNRF3 (E3 ubiquitin-protein ligase ZNRF3) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Adrenocortical carcinoma.
- 1 · What it is
ZNRF3 (E3 ubiquitin-protein ligase ZNRF3) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Adrenocortical carcinoma.
- 2 · What goes wrong in cancer
E3 ubiquitin-protein ligase that acts as a negative regulator of the Wnt signalling pathway by mediating the ubiquitination and subsequent degradation of Wnt receptor complex components Frizzled and LRP6.
- 3 · How drugs use it
No product in this corpus aims at ZNRF3 yet. Because the protein is lost rather than overactive, drugs either restore its function or exploit the weakness its loss leaves (synthetic lethality).
External identifiers
Sources: HGNC HGNC:18126 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q9ULT6 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000183579 (association with cancer (MONDO_0004992) 0.55; (GraphQL API, CC0)); IntOGen ZNRF3 (driver in 1 cohort (Act 0, LoF 1); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Biology
E3 ubiquitin-protein ligase that acts as a negative regulator of the Wnt signalling pathway by mediating the ubiquitination and subsequent degradation of Wnt receptor complex components Frizzled and LRP6. Acts on both canonical and non-canonical Wnt signalling pathway. Acts as a tumour suppressor in the intestinal stem cell zone by inhibiting the Wnt signalling pathway, thereby restricting the size of the intestinal stem cell zone. Along with RSPO2 and RNF43, constitutes a master switch that governs limb specification. Location: Cell membrane (UniProt). Locus 22q12.1 (HGNC).
- Adrenocortical carcinoma: IntOGen driver in 1 cohort (ACC)
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: IntOGen calls it a loss-of-function (LoF) driver in 1 cohort. Evidence tier "cohort-driver" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"ZNRF3" OR ABSTRACT:"ZNRF3" OR TITLE:"zinc and ring finger 3" OR ABSTRACT:"zinc and ring finger 3" OR TITLE:"E3 ubiquitin-protein ligase ZNRF3" OR ABSTRACT:"E3 ubiquitin-protein ligase ZNRF3" OR TITLE:"KIAA1133" OR ABSTRACT:"KIAA1133" OR TITLE:"BK747E2.3" OR ABSTRACT:"BK747E2.3" OR TITLE:"FLJ22057" OR ABSTRACT:"FLJ22057") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about ZNRF3, not a curated reading list.
Similar pages
not linked directly; found by shared links- TargetPRKAR1A
Shares Adrenocortical carcinoma, IntOGen, Open Targets Platform.
- TargetDAXX
Shares Adrenocortical carcinoma, IntOGen, Open Targets Platform.
- TargetBCOR
Shares Adrenocortical carcinoma, IntOGen, Open Targets Platform.
- TargetSETBP1
Shares Adrenocortical carcinoma, IntOGen, Open Targets Platform.
- TargetATRX
Shares Adrenocortical carcinoma, IntOGen, Open Targets Platform.
- TargetTNC
Shares Adrenocortical carcinoma, IntOGen.
- TargetCTNNB1
Shares Adrenocortical carcinoma, IntOGen, Open Targets Platform.